Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Phase II Chemotherapy with Aclacinomycin-A for Renal Cell Carcinoma

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase II

Treatment

Closed

over 18

WSU-C-40981

Objectives

I.  Determine the response rate and remission duration in adult patients with 
renal cell carcinoma treated with aclacinomycin-A on a weekly iv schedule.
II.  Further define the qualitative and quantitative toxicities of this 
treatment.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Adult patients with histologically 
proven adenocarcinoma of the kidney or a renal angiogram compatible with that 
diagnosis.  The minimum expected survival must be 6 weeks, and the performance 
status must be 3 or greater.  There may be no radiotherapy or chemotherapy 
during the 4 weeks prior to entry, and patients must have recovered from the 
toxic effects of previous therapy.  Patients may not have had more than one 
previous chemotherapy trial.  There must be measurable disease; marrow, 
kidney, and liver function must be adequate.

Expected Enrollment

At least 14 patients with previous chemotherapy and 14 without previous 
chemotherapy will be entered.  Protocol closed 12/82 with adequate accrual.

Outline

Nonrandomized study.
Single-agent Chemotherapy.  Aclacinomycin-A, ACM-A, NSC-208734.

Trial Contact Information

Trial Lead Organizations

Barbara Ann Karmanos Cancer Institute

Michael Samson, MD, Protocol chair(Contact information may not be current)
Ph: 313-576-1000 ext. 3327

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.